Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03379311
Study type Interventional
Source Allakos, Inc.
Contact
Status Completed
Phase Phase 1
Start date February 26, 2018
Completion date August 8, 2019

See also
  Status Clinical Trial Phase
Completed NCT05076084 - Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis
Recruiting NCT02057822 - Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months N/A
Completed NCT03464435 - A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Phase 4
Completed NCT00445120 - Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment Phase 2/Phase 3
Recruiting NCT03557203 - Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis
Completed NCT01211327 - Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Phase 4
Completed NCT05353101 - Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial Phase 1
Not yet recruiting NCT04705584 - Topical Immuonosuppressant Drugs in Spring Catarrh N/A
Completed NCT00426023 - Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis Phase 3
Completed NCT01751126 - Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis Phase 3
Recruiting NCT02456025 - Topical Tacrolimus in Vernal Keratoconjunctivitis Phase 4